Navigation Links
Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011
Date:10/21/2011

se group and 116.7 hours for patients receiving the placebo. Time to resolution of symptoms for the low dose group were less than for the placebo, but the difference was not statistically significant (P=0.521). Patients in the 600 mg NTZ treatment group also experienced statistically significant reductions in quantitative viral shedding compared to patients receiving the placebo (P=0.0006). Adverse events were similar for the three treatment groups except for a higher rate of mild diarrhea in the 600 mg treatment group (8.1%) compared to the placebo treatment group (3.3%).

About the Phase 2 Clinical Trials

Two Phase 2 clinical trials, one in pediatric patients age 1 to 11 years, and another in adults and adolescents age 12 – 65 years, were conducted at a single center in Cajamarca, Peru.  Patients were enrolled based upon symptoms consistent with influenza (fever, at least one respiratory symptom and one constitutional symptom) and randomly assigned to receive treatment with NTZ or placebo in double-blind fashion.  Patients in the pediatric study received 100 mg NTZ (age 12 – 47 months), 200 mg NTZ (age 4 – 11 years) or placebo twice daily for five days as an oral suspension.  Patients enrolled in the study of adults and adolescents received 500 mg NTZ or placebo twice daily for five days as an oral tablet.  Identification of respiratory viruses at baseline was performed by ELISA.  Patients were visited daily by a study nurse to monitor the health of the patients, ensure compliance with the study medication and recording of symptoms in a patient diary, and to collect tissue with nasal secretions, and patients were followed up at study day 7.  The primary efficacy endpoint was time from first dose to alleviation of symptoms (all symptoms absent or mild and remained so for 24 hours).  

One-hundred children, median age 3 years, were enrolled in the pediatric trial (50 per tre
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
5. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
6. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
7. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
10. Romark Announces Data Presented at AASLD Meeting 2010
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015 PharmaEngine, Inc. (TWO:4162) today ... (NASDAQ: MACK ) with its sublicensing partner, ... announced that Baxter has submitted a marketing authorization ... for MM-398 (irinotecan liposome injection), also known as ... pancreas who have been previously treated with gemcitabine-based ...
(Date:5/4/2015)...  Oncobiologics, Inc., a biotherapeutics company focused on ... completed the construction of its GMP commercial launch ... Cranbury, New Jersey . The ... to utilize multiple technologies that enable rapid deployment ... use of the latest single-use technologies, the facility ...
(Date:5/4/2015)... HeartWare International, Inc . (NASDAQ: HTWR ), a leading ... revolutionizing the treatment of advanced heart failure, today announced that ... present at the Bank of America Merrill Lynch 2015 Health ... Thursday, May 14, 2015, at 10:00 a.m. PT (1:00 p.m. ... at the conference will be available via a link on ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3HeartWare Presentation At Bank Of America Merrill Lynch 2015 Health Care Conference To Be Webcast 2
... a dynamic, service-oriented healthcare technology company has announced an ... and Practice Management software products. This update will enable ... the requirements set forth by the Centers for Medicare ... (Logo: http://photos.prnewswire.com/prnh/20101115/NY01712LOGO ) Currently, SequelMed ...
... capital, a burdensome and uncertain regulatory environment and lack ... the biggest threats to the biomedical industry,s growth over ... surveyed by CHI-California Healthcare Institute, BayBio and PwC US. ... quarters (74 percent) of biomedical industry CEOs surveyed said ...
Cached Medicine Technology:SequelMed Announces ANSI 5010 Upgrade for Its Users 2Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 2Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 3Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 4Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation 5
(Date:5/4/2015)... New findings released today from a ... show that people diagnosed with a brain tumor needed ... clinical trials, at the time of diagnosis, and had ... about their course of treatment. The release of these ... brain tumor volunteer network, the ABTA CommYOUnityâ„¢, dedicated to ...
(Date:5/4/2015)... 04, 2015 Sheltering Arms announced that ... Hale House. The Mother Hale Learning Center meets a ... Childhood Education. Sheltering Arms will begin operating the site ... served by the center. , Opened in 2006, the ... weeks to five years, many of whom come from ...
(Date:5/4/2015)... May 04, 2015 Elisabeth Rosenthal’s ... a stir and showed the healthcare fraternity as ... healthcare procedure, the downside of balance billing. In ... healthcare provider billing a patient for the difference ... reimburse and what the provider chooses to charge. ...
(Date:5/4/2015)... Pennsylvania (PRWEB) May 04, 2015 World ... and hand cycle ride in the last decade arrived ... riding 110 miles in two days from the Pentagon ... non-profit saw 581 registered disabled and able-bodied participants work ... of America recognizes and honors the commitment and sacrifices ...
(Date:5/4/2015)... May 04, 2015 Fast on the ... documentary Trace Amounts, and Allison Folmar, JD, join over ... held internationally. , On Sunday, May 24, the conference ... autism possible?" Are you interested in Ryan Hinds' recovery ... winning our war against autism was written by ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Sheltering Arms Acquires the Mother Hale Learning Center 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 2Health News:Out of Network Balance Billing Without Being Viewed as Fraud 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4
... , WEDNESDAY, May 30 (HealthDay News) -- ... pneumonia patients, researchers say. The new study included ... who were admitted to hospitals and private practices in ... Community-acquired pneumonia, one of the leading infectious diseases in ...
... , , , , , ... , AUDIO: Smoking researchers at ... Click here for more information. , ... , , , , , ...
... it is beneficial to have a loved one present ... by researchers at the Johns Hopkins Bloomberg School of ... older adults suffering from poor mental health. They examined ... or hinders physician visit processes and found that older ...
... that can rapidly screen cells for leukemia or HIV ... can produce three-dimensional focusing of a stream of cells, ... counting CD4 cells," said Tony Jun Huang, associate professor ... of the diagnoses are done using flow cytometry." ...
... Henry Ford Hospital dermatologists say skin transplant surgery is ... skin disease vitligo. In a first study of its ... up to six months after surgery and found that the ... skin color. In eight patients with localized vitiligo, the treated ...
... who are blind in one side of their visual ... side. After passively hearing sounds for an hour, their ... of their visual field improved significantly. Neural pathways that ... this effect. "We have embarked on a whole new ...
Cached Medicine News:Health News:Genes predict if medication can help you quit smoking 2Health News:Genes predict if medication can help you quit smoking 3Health News:Genes predict if medication can help you quit smoking 4Health News:Patient mental health overlooked by physician when a family member is present 2Health News:Biochip-based device for cell analysis 2Health News:Biochip-based device for cell analysis 3Health News:Skin transplant offers new hope for vitiligo patients 2Health News:Hear to see: New method for the treatment of visual field defects 2
Adult size. Clear plastic. Accommodates either eye. Packaged 12 per box. Available in either adult or pediatric size....
... Flow rate: 45 ... micron. For filtering fluids ... in table; bi-directional membrane ... kg/cm2 (75 psi) via ...
Straight, right side cutting, 1.5 mm x 4 mm bite, length of shaft 115 mm, overall length 6.3 inches....
20 mm. Plastic, methylmethacrylate. Supplied sterile....
Medicine Products: